Back to results
US 2022/0023302 A1Published application
Pde9 inhibitors for treating sickle cell disease
AssigneeImara Inc.
InventorsNiels SVENSTRUP, David TISI, Jeffrey WORTHINGTON, Vanik PETROSSIAN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
Claims43
An pharmaceutical composition comprising:
- (i) about 10.0 mg/mL of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
- and
- (ii) an excipient base comprising about 2.0 mg/mL of potassium sorbate, about 5.0 mg/mL sucralose, about 5.0 mg/mL citric acid, or any combination thereof, wherein the pharmaceutical composition is in the form of an oral solution suitable for administration to a patient.
A pharmaceutical composition comprising:
- 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
- and an excipient base, wherein the composition is in the form of an oral liquid solution.
Dependencies are inferred from the claim text.